Skip to main content
Back
HKMPY logo

Hikma Pharmaceuticals PLC

Data quality: 100%
HKMPY
OTC Healthcare Drug Manufacturers - Specialty & Generic
$32.98
▼ $1.15 (-3.36%)
Mkt Cap: 3.63B
Also listed as HKMPF OTC
Day Range
$32.98 $34.88
52-Week Range
$31.80 $56.94
Volume
550
50D / 200D Avg
$39.84 / $45.96
Prev Close
$34.13

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 9.0 0.4
P/B 1.4 2.9
ROE % 16.4 3.7
Net Margin % 12.0 3.8
Rev Growth 5Y % 7.1 10.0
D/E 0.6 0.2

Key Takeaways

Revenue grew 7.08% annually over 5 years — modest growth
ROE of 16.44% — decent returns on equity
Generating 162.38M in free cash flow
P/E of 9.01 — trading at a low valuation
PEG of 0.89 suggests growth is underpriced
Capital efficient — spends only 5.88% of revenue on capex

Growth

Revenue Growth (5Y)
7.08%
Revenue (1Y)7.35%
Earnings (1Y)12.24%
FCF Growth (3Y)-36.60%

Quality

Return on Equity
16.44%
ROIC11.06%
Net Margin12.00%
Op. Margin18.63%

Safety

Debt / Equity
0.64
Current Ratio1.82
Interest Coverage5.89

Valuation

P/E Ratio
9.01
P/B Ratio1.40
EV/EBITDA7.92
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.35% Revenue Growth (3Y) 8.06%
Earnings Growth (1Y) 12.24% Earnings Growth (3Y) 45.63%
Revenue Growth (5Y) 7.08% Earnings Growth (5Y) -1.09%
Profitability
Revenue (TTM) 3.36B Net Income (TTM) 402.94M
ROE 16.44% ROA 7.11%
Gross Margin 40.04% Operating Margin 18.63%
Net Margin 12.00% Free Cash Flow (TTM) 162.38M
ROIC 11.06% FCF Growth (3Y) -36.60%
Safety
Debt / Equity 0.64 Current Ratio 1.82
Interest Coverage 5.89 Dividend Yield 0.04%
Valuation
P/E Ratio 9.01 P/B Ratio 1.40
P/S Ratio 1.08 PEG Ratio 0.89
EV/EBITDA 7.92 Dividend Yield 0.04%
Market Cap 3.63B Enterprise Value 4.95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.36B 3.13B 2.88B 2.52B 2.55B
Net Income 402.94M 359.00M 190.00M 188.00M 421.00M
EPS (Diluted) 3.62 3.22 1.72 1.68 3.62
Gross Profit 1.34B 1.42B 1.41B 1.24B 1.30B
Operating Income 625.46M 612.00M 367.00M 282.00M 582.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.67B 5.13B 4.68B 4.47B 4.37B
Total Liabilities 3.07B 2.81B 2.47B 2.32B 1.91B
Shareholders' Equity 2.59B 2.31B 2.20B 2.14B 2.45B
Total Debt 1.65B 1.31B 1.19B 1.28B 846.00M
Cash & Equivalents 328.00M 188.00M 205.00M 270.00M 426.00M
Current Assets 2.64B 2.26B 2.10B 2.00B 2.09B
Current Liabilities 1.45B 1.98B 1.34B 1.08B 1.02B

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#349 of 658
27

Recent Activity

Entered Contrarian Investing (David Dreman)
Mar 24, 2026